Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.45 |
| ▸ | TUBB | P07437 | 3/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933958 | 0.85 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MAPT | |
| SCHEMBL7923577 | 0.84 | ACHE (0.63) | PTGS2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL429756 | 0.80 | ACHE (0.59) | PTGS2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL10080322 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2CYP1A2MAPTCYP3A4TDP1 | |
| SCHEMBL12264984 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP1A2CYP2C19MAPTTP53 | |
| SCHEMBL6947358 | 0.78 | ACHE (0.56) | PTGS2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL1337032 | 0.78 | ACHE (0.56) | PTGS2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL21821361 | 0.78 | THRA (0.47) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30522290 | 0.78 | THRA (0.47) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22542317 | 0.77 | ALOX5 (0.46) | PTGS2ALOX15ALOX12CYP1A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | PTGS2 4402/4885TUBB1 2492/4885TUBB4A 2910/4885 |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | PTGS2 2553/4885TUBB1 1697/4885TUBB4A 1556/4885 |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | PTGS2 2604/4885TUBB1 1902/4885TUBB4A 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.